Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Iowa City, Iowa 52242


Purpose:

The purpose of this trial is to determine the safety and efficacy of HuMax-CD20 as a treatment for Chronic Lymphocytic Leukemia.


Criteria:

Inclusion Criteria: - Chronic Lymphocytic Leukemia - Circulating lymphocytes above a specific level - Circulating lymphocytes showing certain markers Exclusion Criteria: - Previous treatment with rituximab or alemtuzumab within 6 months prior to enrollment in study. - Previous stem cell transplantation. - Received any of the following treatments within 4 weeks prior to entering this trial: A) Anti-cancer therapy, B) Glucocorticoids unless less than 10 mg per day, C) Radiotherapy. - HIV positivity. - Hepatitis B or hepatitis C. - Other cancerous diseases, except certain skin cancers and cervix cancer. - Certain serious medical conditions, including kidney or liver disease, some psychiatric illnesses, and stomach, heart, hormonal, nerve or blood diseases. - Participation in another trial with a different new drug 4 weeks prior to enrollment in study. - Current participation in any other clinical study. - Pregnant or breast-feeding women. - Women of childbearing age who are unable or unwilling to use adequate contraception.


NCT ID:

NCT00093314


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

Iowa City, Iowa 52242
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 15, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.